Amyotrophic lateral sclerosis caused by FUS mutations: advances with broad implications

Area of Science:

• Neuroscience
• Genetics
• Molecular Biology

Background:

• Autosomal dominant mutations in the FUS gene are linked to amyotrophic lateral sclerosis (ALS).
• FUS mutations are found in 0.3-0.9% of ALS patients, causing FUS-ALS, a condition with early onset and rapid progression.
• Cytoplasmic accumulation of FUS protein due to disrupted nuclear localization is a hallmark of FUS-ALS.

Purpose of the Study:

• To summarize the genetic basis, clinical characteristics, and pathogenic mechanisms of FUS-mutation-associated ALS (FUS-ALS).
• To highlight the differences between FUS-ALS and frontotemporal dementia.
• To review current therapeutic strategies for FUS-ALS.

Main Methods:

• Review of genetic and neuropathological findings in FUS-ALS.
• Analysis of experimental models to understand disease mechanisms.
• Overview of therapeutic approaches currently in development.

Main Results:

• FUS mutations lead to distinct clinical presentations in ALS, varying in age of onset and progression rate.
• FUS protein inclusions are observed in both FUS-ALS and some frontotemporal dementia cases, but with key genetic and pathological differences.
• Experimental models have elucidated potential pathogenic pathways in FUS-ALS.

Conclusions:

• FUS mutations represent a distinct genetic cause of ALS with specific clinical and pathological features.
• Understanding FUS protein's role in neurodegeneration is crucial for developing targeted therapies.
• Antisense oligonucleotide therapy to silence FUS expression is a promising therapeutic strategy currently in development for FUS-ALS.